Pasithea Therapeutics (KTTA) Stock Price

Pasithea Therapeutics Price

NASDAQ·CLOSED
0.50
+0.00 (+0.00 %)
Market closed

The stock trades about 71% above its 52-week low.

Pasithea Therapeutics stock price

Access this data via the Eulerpool API

Pasithea Therapeutics business model & stock analysis

Frequently asked questions about Pasithea Therapeutics

7 analysts currently rate the Pasithea Therapeutics stock: 6 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Pasithea Therapeutics share trades at 0.44 EUR (0.50 USD).

The Pasithea Therapeutics share (KTTA) is listed on 1 stock exchanges, including: NASDAQ (KTTA).

No history available for Pasithea Therapeutics.

The revenue cannot currently be calculated for Pasithea Therapeutics.

The expected profit of Pasithea Therapeutics is -947,720.05 USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Pasithea Therapeutics is currently -0.65. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pasithea Therapeutics stock.

The P/S cannot be calculated for Pasithea Therapeutics currently.

The Eulerpool Quality Score for Pasithea Therapeutics is 2/10.

The ISIN of Pasithea Therapeutics is US70261F2020. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Pasithea Therapeutics is KTTA. The ticker symbol is used to trade Pasithea Therapeutics shares on the stock exchange.

Pasithea Therapeutics paid dividends every year for the past 0 years.

Pasithea Therapeutics is assigned to the 'Health' sector.

The dividends of Pasithea Therapeutics are distributed in USD.

Fair ValueTerminal
0.41 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website pasithea.com
Currency
USD
Initial public offering
Aug 13, 2021
ISIN
US70261F2020
Cusip
70261F103
Market capitalization
52-Week Range
0.29–1.47USD
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
0.00
P/E ratio
P/Ee 2024
—
P/Ee 2025
-0.33
P/Ee 2026
-0.65
P/Ee 2027
-1.07
P/Ee 2028
-0.89
P/S
P/Se
—
EV/EBIT
0.98
P/B Ratio
0.03
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-68.22 %
Gross Margin
—
EBIT Margin
—
Net Margin
—
EPS (Earnings Per Share)
-13.01 USD
Net Debt / EBIT
1.02
Debt/Equity
0.00
Last updated Sep 27, 2026, 6:36 PM

Pasithea Therapeutics Peer Group

Pasithea Therapeutics Ticker

NASDAQ · KTTA